Rheumatoid Arthritis Posts on Medivizor
Navigation Menu

Rheumatoid Arthritis Posts on Medivizor

Obesity and Rheumatoid arthritis: is disease progression worse and does adalimumab improve symptoms?

Posted by on Sep 17, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated if the response to rheumatoid arthritis (RA) treatment is worse in obese patients. They found that obese patients with RA have a worse clinical response than non-obese patients do. Some background Rheumatoid arthritis (RA) is an inflammatory condition. Fat tissue contains high levels of inflammatory chemicals....

Read More

Can ultrasound of the joints predict remission in rheumatoid arthritis?

Posted by on Sep 2, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated if an ultrasound of the joints (musculoskeletal) can predict if remission can be achieved in patients with rheumatoid arthritis (RA). They found that ultrasound can predict if a patient with RA will achieve remission. Some background The aim of treatment for rheumatoid arthritis (RA) is to reduce disease activity....

Read More

Evaluating predictors for poor methotrexate response in patients with rheumatoid arthritis: can co-treatment with adalimumab improve disease symptoms?

Posted by on Aug 28, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated if there are disease features that can predict if a patient with rheumatoid arthritis will respond well to methotrexate treatment. They found that higher disease activity at early stages of treatment predicted a poor treatment response in these patients. Some background Treatment of rheumatoid arthritis (RA)...

Read More

Clinical Trials Today

Clinical Trials Today

Posted by on Aug 26, 2018 in Benign prostatic hyperplasia, Blog, Breast cancer, Colorectal cancer, Coronary artery disease, Diabetes mellitus, Erectile dysfunction, Hodgkin's lymphoma, Hypertension, Infertility, Kidney stones, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Nocturia, Non-Hodgkin lymphoma, Overactive bladder, Parkinson's Disease, Prostate cancer, Rheumatoid Arthritis, Stroke, Urinary incontinence, Urinary tract infection | 4 comments

Prior to the 20th century, most people lived about 47 years in the developed world because of infectious diseases. In 1940, the first use of penicillin to treat infectious diseases occurred and penicillin became available in 1945 to the general public. Science and research conducted throughout the 1950s, 60s, and 70s, created more antibiotics so that life...

Read More

Does tocilizumab treatment result in improved work productivity in patients with rheumatoid arthritis?

Posted by on Aug 13, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated whether tocilizumab (Actemra) treatment improves work productivity in patients with rheumatoid arthritis. They found that house workers treated with tocilizumab were more productive and better quality of life compared to patients taking synthetic disease-modifying drugs. Some background One of the...

Read More

Is an infliximab biosimilar safe and effective for methotrexate-resistant rheumatoid arthritis?

Posted by on Aug 13, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated if an infliximab (Remicade) biosimilar is safe and effective to treat rheumatoid arthritis. They found that the infliximab biosimilar PF-06438179/GP1111 was similarly effective as standard infliximab and well tolerated. Some background Biosimilars are medicines that act in the same way as the original...

Read More

Assessing the potential of certolizumab pegol treatment for moderate/severe rheumatoid arthritis: is it a matter of time?

Posted by on Aug 13, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the timepoint at which certolizumab pegol treatment is effective in treating rheumatoid arthritis. They found that the effectiveness of certolizumab pegol treatment at 12 weeks predicts future treatment success at 52 weeks. Some background Certolizumab pegol (CZP) is a new biologic drug that blocks activity of...

Read More

Upadacitinib: a safe and effective rheumatoid arthritis treatment for patients resistant to csDMARDs

Posted by on Aug 9, 2018 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated whether upadacitinib is a safe and effective treatment for unresponsive patients with rheumatoid arthritis (RA). They concluded that upadacitinib improved RA symptoms in combination with csDMARDs and was well tolerated.  Some background ne type of medication used to treat rheumatoid arthritis...

Read More